InDex Pharmaceuticals provides complementary information on the phase III program CONCLUDE with cobitolimod
STOCKHOLM, Feb. 14, 2023 /PRNewswire/ — InDex Pharmaceuticals Holding AB (publ) is today making a presentation with CEO Jenny Sundqvist available in light of the press release issued January 27, 2023 regarding the updated timeline of the CONCLUDE program. The presentation highlights the…
Comments Off on InDex Pharmaceuticals provides complementary information on the phase III program CONCLUDE with cobitolimod